Dehydroepiandrosterone for systemic lupus erythematosus (Q24243533)

1

0 references

Corri Black

2

0 references

Linda McIntyre

3

0 references

Pamela Royle

4

0 references

Sian Thomas

Cochrane Database of Systematic Reviews

5

0 references

publication date

17 October 2007

0 references

published in

0 references

cites work

Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

An open study of dehydroepiandrosterone in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Ethnic difference in the prevalence of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Bisphosphonates for steroid induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

The safety and efficacy of MMF in lupus nephritis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Incidence of systemic lupus erythematosus. Race and gender differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Lupus in Hong Kong Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Combined oral contraceptives in women with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Biologic agents and innovative interventional approaches in the management of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

Clinical trial design in systemic lupus erythematosus: lessons learned and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

7 January 2021

Long-term treatment of systemic lupus erythematosus with cyclosporin A

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

7 January 2021

Systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

7 January 2021

Undiagnosed systemic lupus erythematosus in the community

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

7 January 2021

Clinical profile of Chinese patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005114.PUB2

7 January 2021